High-Value Pharma and Biotech Partnerships Emerging from China

Recent B2B investment conferences between Pakistan and China have yielded over $1 billion in commitments and MoUs across pharmaceuticals, biotechnology, and healthcare. These agreements focus on local production of vaccines, pharmaceutical raw materials, and high-value medical devices.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.